Open AccessPOTENTIAL THERAPIES FOR TREATMENT OF COVID-19
Author(s) -
Beatriz Gasser,
Ricardo Andrés Ramírez Uscátegui
Publication year - 2020
Publication title -
revista de ciência veterinária e saúde pública
Language(s) - English
Resource type - Journals
ISSN - 2358-4610
DOI - 10.4025/revcivet.v7i1.55502
Subject(s) - medicine , hydroxychloroquine , lopinavir , intensive care medicine , ards , clinical trial , ritonavir , adverse effect , chloroquine , pneumonia , covid-19 , disease , pharmacology , immunology , viral load , infectious disease (medical specialty) , lung , human immunodeficiency virus (hiv) , malaria , antiretroviral therapy
Since discovery of the novel coronavirus (SARS-CoV-2) in December of 2019, this viral pneumonia originated in Wuhan, China quickly spread around the world. This new disease, called COVID-19 can cause Acute Respiratory Distress Syndrome (ARDS) due to an uncontrolled inflammatory response like sepsis, that leads to multiple organ failure and even death. Several pharmacotherapeutics alternatives are being tested over the world, looking for most diverse drugs that might be able to fight the infection. The objective of this paper is to review the main pharmacotherapeutics techniques development, as remdesivir, chloroquine/hydroxychloroquine, lopinavir plus ritonavir, interferon-β, ivermectin, anticoagulants, convalescent plasma and vaccine, currently undergoing clinical trials in order to evaluate its effectiveness and safety to combat the COVID-19, presenting their characteristics, possible adverse effects and main scientific findings of its potential action. In conclusion, some therapies presented promising in-vitro results or in the treatment of some patients, nonetheless, multicentric blinded placebo controlled clinical trials are necessary to determine their effectiveness, safety, dosage, and best time point of treatment.